Answer
In patients with advanced and/or metastatic cancer, clarithromycin increased abemaciclib plasma exposure 3.4-fold and the combined unbound potency-adjusted plasma exposure of abemaciclib and its active metabolites 2.5-fold.
Sources for this answer
- VerzeniosEli Lilly and Company Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 22Document updated
Sources checked